Skip to content
2000
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
side by side viewer icon HTML

Abstract

Background

Olanzapine is an atypical antipsychotic drug for treating bipolar disorders and Schizophrenia. Regardless of being used as a common antipsychotic drug, there are reports of hepatic abnormalities caused by using Olanzapine. Silymarin and Vitamin C have been shown to have hepatoprotective effects.

Objective

The purpose of the present study was to study the hepatotoxic effects of Olanzapine and the hepatoprotective role of Silymarin and Vitamin C on the Liver of Albino rats.

Methods

The study was conducted on 24 albino rats. The animals were randomly divided into four groups of six rats each: Group A consisted of six rats and served as the control group; Group B consisted of six rats who received orally 4mg/kg of Olanzapine daily; Group C consisted of six rats who received 4mg/kg of Olanzapine plus 200mg/kg of Silymarin daily and Group D consisted of six rats which received orally 4mg/kg of Olanzapine plus 15mg/kg of Vitamin C daily. The animals were sacrificed in two sittings at four and eight weeks, and tissues were processed by routine histopathological technique. The liver enzymes (AST, ALP, ALT) were calculated and analyzed statistically using one-way ANOVA.

Results

It was found that the liver of rats treated with Olanzapine showed sinusoidal dilatation, sinusoidal congestion, central venous congestion, central venous dilatation, cellular infiltration, and portal triaditis. The liver enzymes (AST, ALP, ALT) were markedly raised in the drug-treated rats, showing Olanzapine as a hepatotoxic agent. On the other hand, Silymarin and Vitamin C) both proved to show an excellent hepatoprotective effect.

Conclusion

Olanzapine administration causes histopathological and biochemical abnormalities in the liver. Vitamin C and Silymarin are both potent hepatoprotective agents against Olanzapine-induced hepatic toxicity.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882324343241217083414
2024-01-01
2025-09-30

  • From This Site

    /content/journals/nemj/10.2174/0102506882324343241217083414
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/nemj/5/1/NEMJ-5-E02506882324343.html?itemId=/content/journals/nemj/10.2174/0102506882324343241217083414&mimeType=html&fmt=ahah

References

  1. PocockG. RichardsC.D. RichardsD.A. Human Physiology.3rd edOxford University PressOxford, UK2006
     [Google Scholar]
  2. MitchellM. RiesenbergR. BariM.A. MarquezE. KurtzD. FalkD. HardyT. TaylorC.C. MitchellC.P. CavazzoniP. A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects.Clin. Ther.200628688189210.1016/j.clinthera.2006.06.00816860171
     [Google Scholar]
  3. De AbagjoF.J. MonteroD. MadurgaM. Garcia RodriguezL.A. Medication reviews in the community: Results of a randomized, controlled effectiveness trial.Br. J. Clin. Pharmacol.586648664200410.1111/j.1365‑2125.2004.02220.x15563363
     [Google Scholar]
  4. KolpeM. RavasiaS. Effect of olanzapine on the liver transaminases.Can. J. Psychiatry200348321010.1177/07067437030480031312728748
     [Google Scholar]
  5. LarryD. RipaultM.P. Hepatotoxicity of psychotropic drugs and drugs of abuse.Drug-induced liver disease.3rd ed KaplowitzN. DeLeveL.D. AmsterdamElsevier201344346210.1016/B978‑0‑12‑387817‑5.00025‑X
     [Google Scholar]
  6. SchrieberS.J. WenZ. VourvahisM. SmithP.C. FriedM.W. KashubaA.D.M. HawkeR.L. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity.Drug Metab. Dispos.20083691909191610.1124/dmd.107.01960418566043
     [Google Scholar]
  7. ParésA. PlanasR. TorresM. CaballeríaJ. ViverJ.M. AceroD. PanésJ. RigauJ. SantosJ. RodésJ. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multicenter trial.J. Hepatol.199828461562110.1016/S0168‑8278(98)80285‑79566830
     [Google Scholar]
  8. PradhanS.C. GirishC. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine.Indian J. Med. Res.2006124549150417213517
     [Google Scholar]
  9. MahliA. KochA. CzechB. PeterbursP. LechnerA. HaunschildJ. MüllerM. HellerbrandC. Hepatoprotective effect of oral application of a silymarin extract in carbon tetrachloride-induced hepatotoxicity in rats.Clinical Phytoscience201511510.1186/s40816‑015‑0006‑z
     [Google Scholar]
  10. SalamoneF. GalvanoF. CappelloF. MangiameliA. BarbagalloI. Li VoltiG. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis.Transl. Res.2012159647748610.1016/j.trsl.2011.12.00322633099
     [Google Scholar]
  11. SolhiH. GhahremaniR. KazemifarA.M. Hoseini YazdiZ. Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial.Caspian J. Intern. Med.20145191224490006
     [Google Scholar]
  12. Tveden-NyborgP. LykkesfeldtJ. Does vitamin C deficiency increase lifestyle-associated vascular disease progression? Evidence based on experimental and clinical studies.Antioxid. Redox Sign.201319172084210410.1089/ars.2013.538223642093
     [Google Scholar]
  13. DasK.K. GuptaA.D. DhundasiS.A. PatilA.M. DasS.N. AmbekarJ.G. Effect of L-ascorbic acid on nickel-induced alterations in serum lipid profiles and liver histopathology in rats.J. Basic Clin. Physiol. Pharmacol.2006171294410.1515/JBCPP.2006.17.1.2916639878
     [Google Scholar]
  14. BhatG.M. ShahN.A. ShahB.A. ShahdadS. ItooM.S. MaqdoomiM.A. Lithium carbonate induced histological changes in the Liver of Albino Rats.IOSR J. Pharm. Biol. Sci.201445489310.9790/3008‑09314548
     [Google Scholar]
  15. CopelandR.A. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis.John Wiley and Sons202310.1002/9781119793304
     [Google Scholar]
  16. BashandyS.A. AlWaselS.H. Carbon tetrachloride-induced hepatotoxicity and nephrotoxicity in rats: Protective role of vitamin C.J. Pharmacol. Toxicol.20116328329210.3923/jpt.2011.283.292
     [Google Scholar]
  17. LuftB. TaylorD. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia.Expert Opin. Pharmacother.20067131739174810.1517/14656566.7.13.173916925501
     [Google Scholar]
  18. SikichL. Maloney Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients.Neuropsychiatr. Dis. Treat.2010674976610.2147/NDT.S661421127693
     [Google Scholar]
  19. ElbakaryR. Histological study of effect of Olanzapine on liver of albino rats with and without vitamin C.Egypt. J. Histol.201740111110.21608/EJH.2017.3692
     [Google Scholar]
  20. ShahR. SubhanF. AliG. UllahI. UllahS. ShahidM. AhmadN. FawadK. Olanzapine induced biochemical and histopathological changes after its chronic administration in rats.Saudi Pharm. J.201624669870410.1016/j.jsps.2015.06.00627829813
     [Google Scholar]
  21. MateenS. RainaK. AgarwalR. Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer.Nutr. Cancer201365suppl. 131110.1080/01635581.2013.78500423682778
     [Google Scholar]
  22. SallerR. MelzerJ. ReichlingJ. BrignoliR. MeierR. An updated systematic review of the pharmacology of silymarin.Complement. Med. Res.2007142708010.1159/00010058117464157
     [Google Scholar]
  23. WuJ.W. LinL.C. TsaiT.H. Drug–drug interactions of silymarin on the perspective of pharmacokinetics.J. Ethnopharmacol.2009121218519310.1016/j.jep.2008.10.03619041708
     [Google Scholar]
  24. GillessenA. SchmidtH.H.J. Silymarin as supportive treatment in liver diseases: A narrative review.Adv. Ther.20203741279130110.1007/s12325‑020‑01251‑y32065376
     [Google Scholar]
  25. AghaeiF. WongA. ZarganiM. SarshinA. FeizolahiF. DerakhshanZ. HashemiM. ArabzadehE. Effects of swimming exercise combined with silymarin and vitamin C supplementation on hepatic inflammation, oxidative stress, and histopathology in elderly rats with high-fat diet-induced liver damage.Nutrition202311511216710.1016/j.nut.2023.11216737611505
     [Google Scholar]
  26. HeZ. LiX. YangH. WuP. WangS. CaoD. GuoX. XuZ. GaoJ. ZhangW. LuoX. Effects of oral vitamin C supplementation on liver health and associated parameters in patients with non-alcoholic fatty liver disease: A randomized clinical trial.Front. Nutr.2021874560910.3389/fnut.2021.74560934595203
     [Google Scholar]
  27. SabiuS. SunmonuT.O. AjaniE.O. AjiboyeT.O. Combined administration of silymarin and vitamin C stalls acetaminophen-mediated hepatic oxidative insults in Wistar rats.Rev. Bras. Farmacogn.2015251293410.1016/j.bjp.2014.11.012
     [Google Scholar]
  28. Khaldoun OularbiH. RichevalC. LebailiN. Zerrouki-DaoudiN. BahaM. DjennasN. AllorgeD. Ameliorative effect of vitamin C against hepatotoxicity induced by emamectin benzoate in rats.Hum. Exp. Toxicol.201736770971710.1177/096032711666102227461011
     [Google Scholar]
  29. SmirnoffN. WheelerG.L. Ascorbic acid in plants: Biosynthesis and function.Crit. Rev. Plant Sci.200019426729010.1080/07352680091139231
     [Google Scholar]
  30. ReboucheC.J. Ascorbic acid and carnitine biosynthesis.Am. J. Clin. Nutr.199154Suppl. 61147S1152S10.1093/ajcn/54.6.1147s1962562
     [Google Scholar]
  31. CurcioA. RomanoA. CuozzoS. Di NicolaA. GrassiO. SchiaroliD. NoceraG.F. PirontiM. Silymarin in combination with vitamin C, vitamin E, coenzyme Q10 and selenomethionine to improve liver enzymes and blood lipid profile in NAFLD patients.Medicina (Kaunas)2020561054410.3390/medicina5610054433080906
     [Google Scholar]
/content/journals/nemj/10.2174/0102506882324343241217083414
Loading
Protective Role of Vitamin C and Silymarin Against Olanzapine-Induced Hepatotoxicity in Albino Rats: A Histopathological and Biochemical Study
NEW Emirates Medical J 5, e02506882324343 (2024); https://doi.org/10.2174/0102506882324343241217083414
/content/journals/nemj/10.2174/0102506882324343241217083414
/content/journals/nemj/10.2174/0102506882324343241217083414
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Olanzapine; Silymarin; Sinusoidal congestion; Sinusoidal dilatation; Vitamin C

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test